CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition

FDA-approved kinase inhibitors are now used for melanoma, including combinations of the MEK inhibitor trametinib, and BRAF inhibitor dabrafenib for BRAFV600 mutations. NRAS-mutated cell lines are also sensitive to MEK inhibition in vitro, and NRAS-mutated tumors have also shown partial response to M...

Descripción completa

Detalles Bibliográficos
Autores principales: Simbulan-Rosenthal, Cynthia M., Gaur, Anirudh, Zhou, Hengbo, AbdusSamad, Maryam, Qin, Qing, Dougherty, Ryan, Aljehane, Leala, Kuo, Li-Wei, Vakili, Sahar, Karna, Kumari, Clark, Havens, McCarron, Edward, Rosenthal, Dean S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662463/
https://www.ncbi.nlm.nih.gov/pubmed/31379943
http://dx.doi.org/10.1155/2019/6486173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662463/
https://www.ncbi.nlm.nih.gov/pubmed/31379943
http://dx.doi.org/10.1155/2019/6486173

Ejemplares similares